Altimmune, Inc. (NASDAQ:ALT) Expected to Earn Q1 2024 Earnings of ($0.30) Per Share

Altimmune, Inc. (NASDAQ:ALT) – Analysts at B. Riley issued their Q1 2024 earnings per share estimates for Altimmune in a report issued on Thursday, March 28th. B. Riley analyst M. Mamtani forecasts that the company will earn ($0.30) per share for the quarter. B. Riley currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Altimmune’s current full-year earnings is ($1.45) per share. B. Riley also issued estimates for Altimmune’s Q2 2024 earnings at ($0.30) EPS.

A number of other equities research analysts also recently commented on ALT. The Goldman Sachs Group initiated coverage on Altimmune in a report on Wednesday, January 24th. They issued a “neutral” rating and a $13.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Altimmune in a research report on Friday, December 1st.

Altimmune Trading Up 14.5 %

NASDAQ ALT opened at $10.18 on Friday. The stock has a 50-day simple moving average of $9.90 and a 200 day simple moving average of $6.71. Altimmune has a 12 month low of $2.09 and a 12 month high of $14.84.

Hedge Funds Weigh In On Altimmune

A number of institutional investors have recently modified their holdings of ALT. Barclays PLC grew its position in Altimmune by 62.0% during the 3rd quarter. Barclays PLC now owns 180,409 shares of the company’s stock worth $470,000 after acquiring an additional 69,014 shares during the last quarter. GSA Capital Partners LLP grew its position in shares of Altimmune by 153.1% in the 3rd quarter. GSA Capital Partners LLP now owns 445,868 shares of the company’s stock valued at $1,159,000 after buying an additional 269,676 shares during the last quarter. Dark Forest Capital Management LP boosted its position in shares of Altimmune by 13.4% during the 3rd quarter. Dark Forest Capital Management LP now owns 230,353 shares of the company’s stock valued at $599,000 after purchasing an additional 27,210 shares in the last quarter. Keudell Morrison Wealth Management bought a new stake in shares of Altimmune during the 3rd quarter valued at about $36,000. Finally, WealthPlan Investment Management LLC bought a new stake in shares of Altimmune during the 3rd quarter valued at about $31,000. Institutional investors and hedge funds own 78.05% of the company’s stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis.